BioHarvest Sciences Inc. Common Stock(BHST)Earnings, Financials & Key Ratios
BHST•NASDAQ
$4.20
$95M mkt cap·Price updated May 6, 2026
AboutBioHarvest Sciences Inc. operates as a biotechnology company. The company operates through Nutraceuticals and Pharmaceuticals segments. It develops botanical synthesis platform technology to grow the ingredients in any plant enzymes or cells. The company is leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions in nutraceuticals and pharmaceuticals verticals. It also operates as a contract development and manufacturing operation services. In addition, the company offers wellness products. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red grapes. The company operates in Israel and the United States. BioHarvest Sciences Inc. is based in Vancouver, Canada.Show more
- Revenue$25M+98.8%
- EBITDA-$6M+37.1%
- Net Income-$13M-2.8%
- EPS (Diluted)-0.80+14.0%
- Gross Margin55.35%+24.5%
- EBITDA Margin-22.78%+68.4%
- Operating Margin-27.75%+64.7%
- Net Margin-51.27%+48.3%
- ROE-970.9%
- ROIC-70.41%+76.3%
- Debt/Equity10.39
- Interest Coverage-3.62+28.7%
BHST Key Insights
BioHarvest Sciences Inc. Common Stock (BHST) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 158.6%
- ✓Efficient asset utilization: 1.0x turnover
✗Weaknesses
- ✗High debt to equity ratio of 10.4x
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 11 (bottom 11%)
- ✗Shares diluted 19.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 51.1x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BHST Price & Volume
BioHarvest Sciences Inc. Common Stock (BHST) stock price & volume — 10-year historical chart
Loading chart...
BHST Growth Metrics
BioHarvest Sciences Inc. Common Stock (BHST) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years158.55%
3 Years128.83%
TTM45.88%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM30.86%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM44.22%
Return on Capital
10 Years-241.04%
5 Years-222.71%
3 Years-257.98%
Last Year-65.06%
BHST Recent Earnings
BioHarvest Sciences Inc. Common Stock (BHST) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (33%)●Beat Revenue 2/12 qtrs (33%)
Q4 2025Latest
Nov 13, 2025EPS
$0.14
Est $0.14
+0.0%
Revenue
$9M
Est $9M
-1.0%
Q3 2025
Aug 11, 2025EPS
$0.15
Est $0.11
-36.4%
Revenue
$9M
Est $9M
-6.0%
Q2 2025
May 15, 2025EPS
$0.13
Est $0.15
+13.3%
Revenue
$8M
Est $9M
-8.2%
Q2 2025
Mar 31, 2025EPS
$0.17
Est $0.12
-41.7%
Revenue
$7M
Est $7M
+0.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 13, 2025 | $0.14vs $0.14+0.0% | $9Mvs $9M-1.0% |
| Q3 2025 | Aug 11, 2025 | $0.15vs $0.11-36.4% | $9Mvs $9M-6.0% |
| Q2 2025 | May 15, 2025 | $0.13vs $0.15+13.3% | $8Mvs $9M-8.2% |
| Q2 2025 | Mar 31, 2025 | $0.17vs $0.12-41.7% | $7Mvs $7M+0.6% |
Based on last 12 quarters of dataView full earnings history →
BHST Peer Comparison
BioHarvest Sciences Inc. Common Stock (BHST) competitors in Consumer and specialty ag systems — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NXRT | 757.54M | 29.85 | -23.69 | -3.24% | -12.67% | -10.13% | 5.18 | |
 GFAI | 10.88M | 0.50 | -0.94 | 0.18% | -32.94% | -69.69% | 0.08 | |
 SIGA | 336.57M | 4.70 | 14.24 | -31.8% | 24.64% | 0% | 0 | |
 XTLB | 357.58K | 3.25 | -0.34 | -227.72% | -25.53% | 0.03 | ||
 LWAY | 405.93M | 26.65 | 29.94 | 13.74% | 6.52% | 17.25% | 0.00 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 BYFC | 86.03M | 9.25 | -2.86 | -3.76% | -9.05% | 0.58 | ||
 EDBL | 85.63K | 0.39 | -0.01 | -1.37% | -115.44% | -112.13% | 0.93 |
Compare BHST vs Peers
BioHarvest Sciences Inc. Common Stock (BHST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BHST Income Statement
BioHarvest Sciences Inc. Common Stock (BHST) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Apr'17 | Apr'18 | Apr'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 218K | 396K | 2.1M | 5.5M | 12.67M | 25.19M | 32.72M |
| Revenue Growth % | - | - | - | - | 81.65% | 430.81% | 161.56% | 130.48% | 98.77% | 45.88% |
| Cost of Goods Sold | 483 | 0 | 0 | 189K | 258K | 1.43M | 4.28M | 7.04M | 11.25M | 13.35M |
| COGS % of Revenue | - | - | - | 86.7% | 65.15% | 68.13% | 77.83% | 55.55% | 44.65% | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 29K▲ 0% | 138K▲ 375.9% | 670K▲ 385.5% | 1.22M▲ 81.9% | 5.63M▲ 362.1% | 13.94M▲ 147.5% | 19.37M▲ 0% |
| Gross Margin % | - | - | - | 13.3% | 34.85% | 31.87% | 22.17% | 44.45% | 55.35% | 59.21% |
| Gross Profit Growth % | - | - | - | - | 375.86% | 385.51% | 81.94% | 362.1% | 147.51% | - |
| Operating Expenses | 93.7K | 160.8K | 4.36M | 2.34M | 6.3M | 9.16M | 11.83M | 15.6M | 20.93M | 25.52M |
| OpEx % of Revenue | - | - | - | 1072.94% | 1591.92% | 435.82% | 215.19% | 123.1% | 83.1% | - |
| Selling, General & Admin | 0 | 0 | 0 | 920K | 4.31M | 4.76M | 9.35M | 12.08M | 15.73M | 19.7M |
| SG&A % of Revenue | - | - | - | 422.02% | 1089.39% | 226.4% | 170.1% | 95.3% | 62.47% | - |
| Research & Development | 0 | 0 | 0 | 1.35M | 1.26M | 4.13M | 2.31M | 3.37M | 4.8M | 5.41M |
| R&D % of Revenue | - | - | - | 617.43% | 319.19% | 196.43% | 41.98% | 26.59% | 19.04% | - |
| Other Operating Expenses | 93.7K | 160.8K | 4.36M | 73K | 726K | 273K | 171K | 154K | 399K | 399K |
| Operating Income | -93.08K▲ 0% | 0▲ 100.0% | -4.36M▲ 0% | -2.31M▲ 47.0% | -6.17M▼ 166.9% | -8.49M▼ 37.7% | -10.61M▼ 25.0% | -9.97M▲ 6.1% | -6.99M▲ 29.9% | -6.14M▲ 0% |
| Operating Margin % | - | - | - | -1059.63% | -1557.07% | -403.95% | -193.02% | -78.65% | -27.75% | -18.77% |
| Operating Income Growth % | 27.13% | 100% | - | 46.96% | -166.93% | -37.71% | -24.98% | 6.09% | 29.87% | - |
| EBITDA | -92.6K | -159.63K | -4.36M | -1.98M | -5.88M | -8.11M | -9.9M | -9.13M | -5.74M | -4.61M |
| EBITDA Margin % | - | - | - | -907.55% | -1484.34% | -385.61% | -180.07% | -72.02% | -22.78% | -14.09% |
| EBITDA Growth % | 27.21% | -72.39% | -2628.18% | 54.57% | -197.1% | -37.89% | -22.14% | 7.82% | 37.12% | 31.46% |
| D&A (Non-Cash Add-back) | 484 | 250 | 0 | 331.53K | 288K | 385.58K | 712K | 840K | 1.25M | 1.53M |
| EBIT | -93.7K | -159.88K | -4.36M | -2.31M | -6.06M | -9.02M | -9.84M | -10.6M | -10.97M | -6.14M |
| Net Interest Income | -6.1K | -3.95K | -780K | -2.25M | -405K | -805K | -1.4M | -1.96M | -1.93M | -5.6M |
| Interest Income | 0 | 0 | 0 | - | 131K | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 6.52K | 3.95K | 780K | 2.25M | 535.89K | 805K | 1.4M | 1.96M | 1.93M | 5.6M |
| Other Income/Expense | 0 | 0 | 4.36M | -3M | -418K | -1.34M | -624K | -2.6M | -5.92M | -5.6M |
| Pretax Income | 0▲ 0% | 0▲ 0% | 0▲ 0% | -5.31M▲ 0% | -6.58M▼ 24.0% | -9.83M▼ 49.3% | -11.24M▼ 14.3% | -12.56M▼ 11.8% | -12.9M▼ 2.7% | -11.74M▲ 0% |
| Pretax Margin % | - | - | - | -2435.78% | -1662.63% | -467.51% | -204.37% | -99.15% | -51.23% | -35.88% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8K | 148K |
| Effective Tax Rate % | - | - | - | 0% | 0% | 0% | 0% | 0% | -0.06% | -1.26% |
| Net Income | 0▲ 0% | 0▲ 0% | 0▲ 0% | -5.31M▲ 0% | -6.58M▼ 24.0% | -9.83M▼ 49.3% | -11.24M▼ 14.3% | -12.56M▼ 11.8% | -12.91M▼ 2.8% | -11.89M▲ 0% |
| Net Margin % | - | - | - | -2435.78% | -1662.63% | -467.51% | -204.37% | -99.15% | -51.27% | -36.33% |
| Net Income Growth % | - | - | - | - | -23.99% | -49.26% | -14.34% | -11.82% | -2.78% | 30.86% |
| Net Income (Continuing) | 0 | 0 | 0 | -5.31M | -6.58M | -9.83M | -11.24M | -12.56M | -12.91M | -11.89M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 3.56M | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.19▲ 0% | -0.21▼ 10.5% | -2.34▼ 1014.3% | -1.75▲ 25.2% | -0.70▲ 60.0% | -0.70▲ 0.0% | -0.70▲ 0.0% | -0.93▼ 32.9% | -0.80▲ 14.0% | -0.68▲ 0% |
| EPS Growth % | 56.82% | -10.53% | -1014.29% | 25.21% | 60% | 0% | 0% | -32.86% | 13.98% | 44.22% |
| EPS (Basic) | -0.19 | -0.21 | -2.34 | -1.75 | -0.70 | -0.70 | -0.70 | -0.93 | -0.80 | - |
| Diluted Shares Outstanding | 416.06K | 578.47K | 1.63M | 2.95M | 9.71M | 12.45M | 13.05M | 13.53M | 16.19M | 17.42M |
| Basic Shares Outstanding | 416.06K | 578.47K | 1.63M | 2.95M | 9.71M | 12.45M | 13.05M | 13.53M | 16.19M | 17.42M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BHST Balance Sheet
BioHarvest Sciences Inc. Common Stock (BHST) balance sheet — assets, liabilities & shareholders' equity
| Line item | Apr'17 | Apr'18 | Apr'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.23K | 281.07K | 868K | 1.24M | 2.24M | 5.67M | 4.32M | 9.05M | 7.86M | 17.84M |
| Cash & Short-Term Investments | 1.85K | 278.19K | 532K | 911K | 1.78M | 4.12M | 1.74M | 5.36M | 2.39M | 10.97M |
| Cash Only | 1.85K | 278.19K | 532K | 911K | 1.78M | 4.12M | 1.74M | 5.36M | 2.39M | 10.97M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.38K | 2.88K | 0 | 281K | 354K | 620K | 722K | 968K | 1.34M | 2.44M |
| Days Sales Outstanding | - | - | - | 470.48 | 326.29 | 107.66 | 47.93 | 27.88 | 19.45 | 23.66 |
| Inventory | 0 | 0 | 0 | 51K | 100K | 928K | 1.38M | 2.47M | 3.65M | 4.43M |
| Days Inventory Outstanding | - | - | - | 98.49 | 141.47 | 236.54 | 117.54 | 127.87 | 118.63 | 110.95 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 80.75K | 107.04K | 4.76M | 779K | 3.07M | 4.54M | 5.07M | 5.95M | 17.14M | 17.35M |
| Property, Plant & Equipment | 80.75K | 107.04K | 0 | 651K | 2.92M | 4.36M | 4.91M | 5.77M | 16.77M | 16.94M |
| Fixed Asset Turnover | - | - | - | 0.33x | 0.14x | 0.48x | 1.12x | 2.20x | 1.50x | 1.94x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 4.76M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 128K | 0 | 0 | 0 | 0 | 0 | 802K |
| Other Non-Current Assets | 0 | 0 | 4.76M | 0 | 144K | 179K | 163K | 179K | 371K | 732K |
| Total Assets | 83.99K▲ 0% | 388.11K▲ 362.1% | 5.63M▲ 1349.3% | 2.02M▼ 64.1% | 5.3M▲ 162.3% | 10.21M▲ 92.5% | 9.39M▼ 8.0% | 15M▲ 59.7% | 25M▲ 66.7% | 35.19M▲ 0% |
| Asset Turnover | - | - | - | 0.11x | 0.07x | 0.21x | 0.59x | 0.84x | 1.01x | 1.14x |
| Asset Growth % | -8.37% | 362.11% | 1349.33% | -64.05% | 162.31% | 92.46% | -7.98% | 59.71% | 66.65% | 211.74% |
| Total Current Liabilities | 165.19K | 35.63K | 27K | 26.47M | 1.89M | 2.92M | 11.52M | 26.47M | 14.26M | 13.19M |
| Accounts Payable | 54.85K | 35.63K | 27K | 403K | 435K | 875K | 1.07M | 1.78M | 3.52M | 3.48M |
| Days Payables Outstanding | 41.48K | - | - | 778.28 | 615.41 | 223.03 | 91.02 | 92.2 | 114.41 | 96.85 |
| Short-Term Debt | 110.34K | 0 | 0 | 23.7M | 0 | 0 | 8.55M | 20.53M | 3.9M | 5.58M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 394K | 836K | 1.3M | 3.86M |
| Other Current Liabilities | 47.1K | 35.63K | 27K | 2.15M | 353K | 1.33M | 698K | 1.57M | 3.66M | 3.69M |
| Current Ratio | 0.02x | 7.89x | 32.15x | 0.05x | 1.18x | 1.94x | 0.38x | 0.34x | 0.55x | 0.55x |
| Quick Ratio | 0.02x | 7.89x | 32.15x | 0.05x | 1.13x | 1.62x | 0.26x | 0.25x | 0.29x | 0.29x |
| Cash Conversion Cycle | - | - | - | -209.31 | -147.65 | 121.17 | 74.46 | 63.56 | 23.67 | 37.76 |
| Total Non-Current Liabilities | 0 | 0 | 1.88M | 2.52M | 5.71M | 4.43M | 3.8M | 3.39M | 9.41M | 14.26M |
| Long-Term Debt | 0 | 0 | 0 | 2.2M | 0 | 0 | 0 | 0 | 0 | 4.39M |
| Capital Lease Obligations | 0 | 0 | 0 | 320K | 2.4M | 2.27M | 1.67M | 1.43M | 9.14M | 37.2M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 1.88M | 7K | 0 | 340K | 123K | 1.96M | 272K | 272K |
| Total Liabilities | 165.19K | 35.63K | 1.91M | 28.99M | 7.6M | 7.35M | 15.32M | 29.86M | 23.67M | 27.45M |
| Total Debt | 110.34K | 0 | 0 | 26.22M | 2.71M | 2.66M | 10.56M | 22.34M | 13.82M | 19.84M |
| Net Debt | 108.49K | -278.19K | -532K | 25.31M | 932K | -1.46M | 8.82M | 16.98M | 11.43M | 8.88M |
| Debt / Equity | - | - | - | - | - | 0.93x | - | - | 10.39x | 10.39x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -4.31x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.93x |
| Interest Coverage | -14.27x | - | -5.58x | -1.03x | -11.51x | -10.55x | -7.59x | -5.08x | -3.62x | -1.10x |
| Total Equity | -81.21K▲ 0% | 352.48K▲ 534.0% | 3.72M▲ 954.5% | -26.97M▼ 825.6% | -2.29M▲ 91.5% | 2.85M▲ 224.4% | -5.93M▼ 307.7% | -14.85M▼ 150.5% | 1.33M▲ 109.0% | 7.74M▲ 0% |
| Equity Growth % | -501.81% | 534.04% | 954.52% | -825.59% | 91.49% | 224.4% | -307.67% | -150.51% | 108.95% | 105.31% |
| Book Value per Share | -0.20 | 0.61 | 2.27 | -9.14 | -0.24 | 0.23 | -0.45 | -1.10 | 0.08 | 0.44 |
| Total Shareholders' Equity | -81.21K | 352.48K | 3.72M | -30.53M | -2.29M | 2.85M | -5.93M | -14.85M | 1.33M | 7.74M |
| Common Stock | 0 | 0 | 0 | 25K | 47.58M | 62.56M | 65.01M | 68.65M | 97.75M | 113.08M |
| Retained Earnings | -409.51K | -598.88K | -5.14M | -41.45M | -49.88M | -59.7M | -70.94M | -83.5M | -96.42M | -105.35M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 13.09K | 8.39K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 3.56M | 0 | 0 | 0 | 0 | 0 | 0 |
BHST Cash Flow Statement
BioHarvest Sciences Inc. Common Stock (BHST) cash flow — operating, investing & free cash flow history
| Line item | Apr'17 | Apr'18 | Apr'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 0 | 0 | 0 | -2.38M | -3.88M | -6.79M | -9.24M | -8.52M | -6.68M | -6.68M |
| Operating CF Margin % | - | - | - | -1093.12% | -978.54% | -323.22% | -168.08% | -67.25% | -26.54% | - |
| Operating CF Growth % | - | - | - | - | -62.61% | -75.33% | -36.02% | 7.78% | 21.57% | -69.99% |
| Net Income | -99.8K | -163.83K | -5.13M | -5.31M | -6.58M | -9.83M | -11.24M | -12.56M | -12.91M | -11.89M |
| Depreciation & Amortization | 0 | 0 | 0 | 324K | 288K | 385.58K | 712K | 840K | 1.25M | 1.53M |
| Stock-Based Compensation | 0 | 0 | 0 | 456K | 1.38M | 3.37M | 1.35M | 563K | 601K | 132K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 99.8K | 163.83K | 5.13M | 1.47M | 1.27M | -627K | 239K | 1.88M | 4.93M | 3.01M |
| Working Capital Changes | 0 | 0 | 0 | 674K | -232K | -96K | -308K | 755K | -555K | -788.68K |
| Change in Receivables | -99 | -1.41K | 0 | -36K | -73K | -266K | -588K | -22K | -594K | -427.56K |
| Change in Inventory | 0 | 0 | 0 | 80K | -49K | -828K | -450K | -1.09M | -1.19M | -1.24M |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 730K | 0 | 1.04M | 603.27K |
| Cash from Investing | 0 | 0 | 0 | -34K | -173K | -1.64M | -1.26M | -1.47M | -3.03M | -2.07M |
| Capital Expenditures | -18.87K | -21.5K | 0 | -34K | -173K | -1.64M | -1.26M | -1.47M | -2.83M | -2.07M |
| CapEx % of Revenue | - | - | - | 15.6% | 43.69% | 78.02% | 22.84% | 11.63% | 11.26% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 18.87K | 21.5K | 0 | 0 | 0 | 0 | 0 | 0 | -192K | 250 |
| Cash from Financing | 73.28K | 435.13K | 2.23M | 2.12M | 4.93M | 10.77M | 8.14M | 13.56M | 6.78M | 18.49M |
| Debt Issued (Net) | 73.28K | 16.47K | 0 | 1.66M | 457K | -332K | 7.66M | 13.15M | 2.04M | 13.49M |
| Equity Issued (Net) | 0 | 453.06K | 0 | 742K | 4.47M | 7.47M | 877K | 534.17K | 4.33M | 5.85M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -34.4K | 2.23M | -251.72K | 0 | 3.64M | -397K | -131.17K | 408K | -850.52K |
| Net Change in Cash | 0▲ 0% | 0▲ 0% | 0▲ 0% | -288K▲ 0% | 872K▲ 402.8% | 2.33M▲ 167.7% | -2.38M▼ 202.0% | 3.62M▲ 252.0% | -2.96M▼ 181.9% | 8.2M▲ 0% |
| Free Cash Flow | 0▲ 0% | 0▲ 0% | 0▲ 0% | -2.42M▲ 0% | -4.05M▼ 67.5% | -8.43M▼ 108.3% | -10.5M▼ 24.5% | -10M▲ 4.8% | -9.52M▲ 4.8% | -10.07M▲ 0% |
| FCF Margin % | - | - | - | -1108.72% | -1022.22% | -401.24% | -190.92% | -78.88% | -37.79% | -30.78% |
| FCF Growth % | - | - | - | - | -67.48% | -108.35% | -24.46% | 4.77% | 4.77% | -1.68% |
| FCF per Share | - | - | - | -0.82 | -0.42 | -0.68 | -0.80 | -0.74 | -0.59 | -0.59 |
| FCF Conversion (FCF/Net Income) | - | - | - | 0.45x | 0.59x | 0.69x | 0.82x | 0.68x | 0.52x | 0.85x |
| Interest Paid | 0 | 533 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BHST Key Ratios
BioHarvest Sciences Inc. Common Stock (BHST) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | - | - | -3509.64% | - | - | -970.9% | -1198.89% |
| Return on Invested Capital (ROIC) | -239.77% | - | -200.43% | -227.51% | - | -37460.29% | -371.05% | -297.49% | -70.41% | -70.41% |
| Gross Margin | - | - | - | 13.3% | 34.85% | 31.87% | 22.17% | 44.45% | 55.35% | 59.21% |
| Net Margin | - | - | - | -2435.78% | -1662.63% | -467.51% | -204.37% | -99.15% | -51.27% | -36.33% |
| Debt / Equity | - | - | - | - | - | 0.93x | - | - | 10.39x | 10.39x |
| Interest Coverage | -14.27x | - | -5.58x | -1.03x | -11.51x | -10.55x | -7.59x | -5.08x | -3.62x | -1.10x |
| FCF Conversion | - | - | - | 0.45x | 0.59x | 0.69x | 0.82x | 0.68x | 0.52x | 0.85x |
| Revenue Growth | - | - | - | - | 81.65% | 430.81% | 161.56% | 130.48% | 98.77% | 45.88% |
BHST Frequently Asked Questions
BioHarvest Sciences Inc. Common Stock (BHST) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BioHarvest Sciences Inc. Common Stock (BHST) reported $32.7M in revenue for fiscal year 2024.
BioHarvest Sciences Inc. Common Stock (BHST) grew revenue by 98.8% over the past year. This is strong growth.
BioHarvest Sciences Inc. Common Stock (BHST) reported a net loss of $11.9M for fiscal year 2024.
Dividend & Returns
BioHarvest Sciences Inc. Common Stock (BHST) has a return on equity (ROE) of -970.9%. Negative ROE indicates the company is unprofitable.
BioHarvest Sciences Inc. Common Stock (BHST) had negative free cash flow of $10.1M in fiscal year 2024, likely due to heavy capital investments.
Explore More BHST
BioHarvest Sciences Inc. Common Stock (BHST) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates